Retinoids and retinoic acid metabolism blocking agents in psoriasis

Retinoids and Carotenoids in Dermatology

Volumn , Issue , 2007, Pages 125-152

  Van de Kerkhof, Peter C M ^a   Verfaille, Christel J ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Barrier Therapeutics NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953273422     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (134)

1. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64: 1137-1139.
2. Bonnekoh B, Gollnick HPM. Topical and systemic retinoids. In: Textbook of Psoriasis. 2nd ed. van de Kerkhof PCM, ed. London: Blackwell Science Ltd. 2003: 247-274.
3. Stuttgen G. Zur Lokal behandlung von keratosen mit Vitamin A-Säure. Dermatologica 1962; 124: 65-80.
4. Peck G, DiGiovanna J. Synthetic retinoids in dermatology. In: The retinoids: Biology, Chemistry and Medicine. 2nd ed. Sporn M, Roberts A, Goodman D, eds. New York: Raven Press Ltd., 1994: 639-658.
5. Frey JR, Schoch MA. Therapeutische Versuche bei Psoriasis mit Vitamin A, zugleich ein Beitrag zur A-Hypervitaminose. Dermatologica 1952; 104: 80.
6. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99: 469-476.
7. Chandraratna RAS. Rational design of receptor-selective retinoids. J Am Acad Dermatol 1998; 39: S124-S128.
8. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994; 30: 581-590.
9. Nagpal S, Thacker SM, Patel S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ 1996; 7: 1783-1791.
10. Duvic M, Nagpal S, Ascano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18-S24.
11. Thacher SM, Vasudevan J, Tsang KY, et al. New dermatological agents for the treatment of psoriasis. J Med Chem 2001; 44(3): 281-297.
12. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol 1998; 39: S134-S138.
13. Tang-Liu DD-S, Matsumoto RM, Usansky JJ. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37: 273-287.
14. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92.
15. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-767.
16. Allergan (U.S.A.). Tazorac® (tazarotene topical cream): prescribing information 2001.
17. Allergan (U.S.A.). Tazorac® (tazarotene topical gel): prescribing information 2003 Dec.
18. Allergan Ltd (U.K.). Zorac 0.05% gel (online). Available from URL: http://emc. medicines.org.uk (accessed 2006 Feb 15).
19. Allergan Ltd (U.K.). Zorac 0.1% gel (online). Available from URL: http://emc.medicines. org.uk (accessed 2006 Feb 15).
20. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38: 705-711.
21. Yi Tzung T, Wu J, Ch, Chen YH, et al. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol 2005; 85: 236-239.
22. Green L, Sadoff W, Lebwohl MG, et al. A clinical evaluation of tazarotene 0.1% gel with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan med Surg 2002; 30: 95-102.
23. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaques psoriasis. J Am Acad Dermatol 1998; 39(Pt 1): 590-596.
24. Gollnick H, Menter A. A combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999; 40(suppl 54): 18-23.
25. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40: 210-212.
26. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22: 1225-1238.
27. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002; 46: 907-913.
28. Koo JY. Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998; 3: S144-S148.
29. Behrens S, Grundmann-Kollmann M, Peter RU, et al. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol 1999; 141(1): 177.
30. Behrens S, Grundmann-Kollman M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000; 42: 493-495.
31. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000; 43: 821-828.
32. Schiener R, Behrens-Williams SC, Pillekamp H, et al. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. Br J Dermatol 2000; 143(6): 1275-1278.
33. Tzaneva S, Honigsmann H, Tanew A, et al. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002; 147(4): 748-753.
34. Veraldi S, Schianchi R. Short-contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003; 206: 347-348.
35. Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 2005; 6: 1725-1734.
36. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004; 22: 467-476.
37. Apfel C, Crettaz M, Siegentaler G, et al. Synthetic retinoids: binding to retinoic acid receptors. In: Retinoids 10 years on. Saurat JH, ed. Basel: Korgen, 1991.
38. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque type psoriasis. Drug Safety 2002; 25: 913-927.
39. Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998; 39: S25-S33.
40. Rollmann O, Vahlquist A. Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. Br J Dermatol 1983; 109: 439-447.
41. Almond-Roesler B, Orfanos CE. Trans-acitretin wird in etretinat rückmetabolisiert. Hautarzt 1996; 47: 173-177.
42. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623-627.
43. Ozawa A, Ohkido M, Haruki Y, et al. Treatment of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999; 26: 141-149.
44. Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133: 711-715.
45. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter trial. J Am Acad Dermatol 1991; 24: 598-602.
46. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999; 41: 2-6.
47. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19: 186-191.
48. Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improved psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988; 18: 655-662.
49. Olsen EA, Weed WW, Meyer CJ, et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686.
50. Torol L, Kadar L, Geiger JM. Acitretin treatment of severe psoriasis. Acta Dermatol Venereol Supl (Stockh) 1989; 146: 104-106.
51. Geiger JM, Czarnetski BM. Acitretin (Ro 10-1670, etretin). Overall evaluation of clinical studies. Dermatologica 1988; 176: 182-190.
52. Lassus A, Geiger JM, Nyblom M, et al. Treatment of severe psoriasis with etretin (R0-10-1670). Br J Dermatol 1987; 117: 333-341.
53. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German Multicenter study. J Am Acad Dermatol 1988; 19: 458-469.
54. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989; 69: 35-40.
55. Gollnick H, Zaun H, Ruzicka T. Relapse rate of severe generalised psoriasis after treatment with acitretin or etretinate. Results of the first randomised double blind multicenter half-year follow-up study. Eur J Dermatol 1993; 3: 442-446.
56. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett 2003; 8: 1-3.
57. Brazalli V, Martinali S, Prestinari F, et al. An impressive therapeutic result in nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 229: 30.
58. De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362.
59. De Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-303.
60. Agnewk L, Bunker CB. Multiple cutaneous squamous carcinoma in psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol 2003; 17: 113-114.
61. DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc 1998; 30: 2771-2775.
62. van de Kerkhof PCM, de Rooij MJM. Multiple squamous cell carcinomas in a psoriatic patient following high dose photochemotherapy and cyclosporin treatment. Response to longterm acitretin maintenance. Br J Dermatol 1997; 136: 276-278.
63. Lebwohl M, Tannis C, Cazasco D. Acitretin suppression of squamous cell carcinoma: a case report and literature review. J Dermatol Treat 2003; 14(2): 3-6.
64. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50: 416-430.
65. Lebwohl M, Drake L, Menter A, et al. Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45: 544-553.
66. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990; 126: 482-486.
67. Lowe N, Prystowski JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991; 24: 591-594.
68. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989; 120: 665-670.
69. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999; 41: 22-24.
70. Spuls PI, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. J Dermatology Treat 2003; 14(2): 17-20.
71. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 26: 682-684.
72. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218-224.
73. Laurahanta J, Geiger JM. a double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989; 121: 107-112.
74. Muchenberger S, Schof E, Simon JC. The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br J Dermatol 1997; 137: 587-589.
75. van de Kerkhof PCM, Cambazard F, Hutchinson F, et al. The effect of the addition of calcipotriol ointment (50 µg/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84-89.
76. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118-121.
77. Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol 2004; 3: 270-272.
78. Spuls PI, Hadi S, Rivera L, et al. Retrospective analysis in the treatment of psoriasis of the palms and soles. J Dermatol Treat 2003; 14(2): 21-25.
79. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003; 22: 187-195.
80. Kazinski K, Joyce KM, Hodson D. The successful use of etanercept in combination therapy for treatment of acrodermatitis Continua Hallopeau. J Drugs Dermatol 2005; 4: 3604.
81. Van Duijnhoven MWF, De Jong EMGJ, Gerritsen WJ, et al. Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol 2005; 15: 1-8.
82. Webber IR, Back DJ. Effect of etretinate on cyclosporin metabolism in vitro. Br J Dermatol 1993; 128: 42-44.
83. van der Veen EF, Ellis CN, Campbell JP, et al. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol 1982; 118: 660.
84. Beck HI, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica 1983; 167: 94-96.
85. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005; 24: 37-45.
86. Koo J, Nguyen Q, Gamba C. Advances in psoriasis therapy. Adv Dermatol 1997; 12: 47-72.
87. Yamauchi PS, Rizk D, Kormili T, et al. Systemic retinoids. In: Therapy of Moderate to Severe Psoriasis. Weinstein GD, Gottlieb AB, eds. New York: Marcel Dekker, Inc, 2003: 137-150.
88. Piskin S, Gurkok F, Ekuklu G, et al. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44: 24-26.
89. Rocha-Pereira P, Santos Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
90. Vahlquist C, Michaelson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987; 67: 12-15.
91. Valquist C, Selinus I, Vessby B. Serum lipids changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm Venereol 1988; 6: 300-305.
92. Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41: 584-588.
93. Van Ditzhuijsen TJ, van Haelst UJ, van Dooren-Greebe RJ, et al. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 1990; 11: 185-188.
94. Mills CM, Marks R. Adverse reactions to oral retinoids. An update. Drug Saf 1993; 9(4): 280-290.
95. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol 1988; 3: 273-288.
96. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189(2): 109-116.
97. Di Giovanna JJ, Sollito RB, Abangan DL. Osteoporosis is a toxic effect in a longterm etretinate therapy. Arch Dermatol 1995; 131: 1321-1322.
98. van Dooren-Greebe RJ, Lemmens JA, de Boo T, et al. Prolonged treatment with oral retinoids in adults: no influence on the prevalence, incidence and severity of spinal abnormalities. Br J Dermatol 1996; 134: 71-76.
99. Naldi L, Griffiths CME. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
100. http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4062S1_02_Allergan-Presentation_files/frame.htm (accessed 15 Feb.2006).
101. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19(9): 2456-2471.
102. Prince HM, McCormack C, Ryan G, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 2001; 42(2): 91-97.
103. Ligand pharmaceuticals Inc. (U.S.A.) Targretin® (bexarotene) capsules, 75 mg: package insert. Available at www.fda.gov/cder/foi/label/1999/21055lbl.pdf (accessed Jan. 2006).
104. Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003; 16(4): 322-330.
105. Bischoff ED, Heyman RA, Lamph WW. Effect of the retinoid X receptor-selective ligand, LGD1069, on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 1999; 91(24): 2118.
106. Bischoff ED, Gottardis MM, Moon TE, et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58(3): 479-484.
107. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56(24): 5566-5570.
108. Gamage SD, Bischoff ED, Burroughs KD, et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther 2000; 295(2): 677-681.
109. Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38(16): 3146-3155.
110. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8(5): 1234-1240.
111. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000; 1(4): 245-250.
112. Smit JV, de Jong EM, van Hooijdonk CA, et al. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 2004; 51(2): 257-264.
113. Smit JV, Franssen ME, de Jong EM, et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004; 51: 249-256.
114. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004; 4(2): 180-188.
115. Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol 1999; 63: 139-188.
116. Petkovich PM. Retinoic acid metabolism. J Am Acad Dermatol 2001; 45(5): S136-S142.
117. Vanden Bossche H, Willemsens S. Retinoic acid and cytochrome P-450. Retinoids 1991; 10: 79-88.
118. Kang S, Duell E, Kim K, et al. Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo. J Invest Dermatol 1996; 107(2): 183-187.
119. Van Wauwe JP, Coene MC, Goossens J, et al. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans- retinoic acid. J Pharmacol Exp Ther 1988; 245(2): 718-722.
120. Van Wauwe J, Coene MC, Goossens J, et al. Effects of cytochrome P-450 inhibition on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990; 252: 365-369.
121. Van Wauwe J, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261(2): 773-778.
122. De Coster R, Wouters W, van Ginckel R, et al. Experimental studies with liarozole (R75251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992; 43: 197-201.
123. Bryson HM, Wagstaff AJ. Liarozole. Drugs Aging 1996; 9(6): 478-484.
124. Lucker G, Heremans A, Boegheim P, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71-75.
125. Lucker G, Verfaille CJ, Heremans A, et al. Topical liarozole in ichthyosis: a doubleblind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 2005; 152: 566-569.
126. Verfaille CJ, Steijlen PM, Blanchet-Bardon C, et al. Phase II and III studies to evaluate the efficacy and safety of oral liarozole and acitretin in the treatment of severe ichthyosis. J Eur Acad Dermatol Venereol 2004; 18(suppl 2): 145.
127. Vandeplassche G, Verfaille CJ, Beger B, et al. Safety of oral liarozole in subjects with ichthyosis or psoriasis. J Eur Acad Dermatol Venereol 2004; 18(suppl 2): 395-396.
128. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995; 133: 426-432.
129. Berth-Jones J, Todd G, Hutchinson P, et al. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol 2000; 143: 1170-1176.
130. Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145(4): 546-553.
131. Vandeplassche G, Beger B, Staszak J, et al. Long-term safety of oral liarozole, a new retinoic acid metabolism blocking agent. J Eur Acad Dermatol Venereol 2005; 19(suppl 2): FC13.14.
132. Stoppie P, Borgers M, Borghgraef P, et al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000; 293(1): 304-312.
133. Rambazole ™ (R115866) Investigational Drug Brochure; version 3.0, Oct. 2005. Data on file, Barrier Therapeutics.
134. Steijlen P, Thissen CA, Bovenschen JH, et al. Oral Rambazole™ in patients with moderate to severe plaque type psoriasis- a pilot trial. J Eur Acad Dermatol Venereol 2005; 19(suppl 2): P06.84.